際際滷shows by User: MikeThompsonMDPhD / http://www.slideshare.net/images/logo.gif 際際滷shows by User: MikeThompsonMDPhD / Mon, 04 Apr 2016 09:28:15 GMT 際際滷Share feed for 際際滷shows by User: MikeThompsonMDPhD #EBMT16 - Social Media in Hematology / Oncology / BMT /slideshow/ebmt16-social-media-in-hematology-oncology-bmt/60443870 thompsonebmt16smintro040416finaledited-160404092815
Thompson @mtmdphd #EBMT16 Social Media Introduction 際際滷s]]>
Thompson @mtmdphd #EBMT16 Social Media Introduction 際際滷s]]> Mon, 04 Apr 2016 09:28:15 GMT /slideshow/ebmt16-social-media-in-hematology-oncology-bmt/60443870 MikeThompsonMDPhD@slideshare.net(MikeThompsonMDPhD) #EBMT16 - Social Media in Hematology / Oncology / BMT MikeThompsonMDPhD Thompson @mtmdphd #EBMT16 Social Media Introduction 際際滷s <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/thompsonebmt16smintro040416finaledited-160404092815-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Thompson @mtmdphd #EBMT16 Social Media Introduction 際際滷s
#EBMT16 - Social Media in Hematology / Oncology / BMT from Mike Thompson, MD, PhD
]]> 11999 14 https://cdn.slidesharecdn.com/ss_thumbnails/thompsonebmt16smintro040416finaledited-160404092815-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-MikeThompsonMDPhD-48x48.jpg?cb=1605128944 *Regarding LinkedIn* I generally don't connect with people on LinkedIn that don't comment on why they think we should connect. See: Use the Favor Test When You're Undecided About a LinkedIn Invitation [7/13/13] - @awsamuel @lifehacker http://ow.ly/AucoV ----------- I am a board certified hematologist / oncologist. I am passionate about clinical trials, basic science and translational research. It is a tragedy that only 2-7% of adults participate in cancer clinical trials (Zon R. et al. ASCO statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008) Improved clinical trial enrollment depends on well designed, interesting trials as well as inf